Back

ViferaXS closes up to €12 million Series A for cancer immunotherapy trials

Verifying
  • ViferaXS closed a Series A financing round led by SPRIND and Huma.
  • The company raised up to €12 million, including grant funding, for oncology development.
  • ViferaXS is advancing Phase II CLL and Phase I AML and FLC programs.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.